

# Quality Notification

## MY-QN-RDS-MolecularLab-2024-031

RDS / Molecular Diagnostics  
Amal Safiyyah  
Version 1  
05-Apr-2024

### Discontinue use of select cobas<sup>®</sup> HCV GT Control Kits

| Product                               | GMMI   | Lot                       |
|---------------------------------------|--|---------------------------|
| KIT COBAS 4800 HCV GT CTLS 10T CE-IVD | 06984339190  | J30965, K06929 and K09615 |
| <b>Instrument/System</b>              | cobas <sup>®</sup> x 480 instrument<br>cobas <sup>®</sup> z 480 analyzer |                           |
| <b>Component</b>                      | Reagent  |                           |
| <b>Target Group</b>                   | Application  |                           |
| <b>Details</b>                        | Customer Information<br>Customer Action                                  |                           |
| <b>Feedback Due Date</b>              | 01-Jul-2024  |                           |

# Discontinue use of select cobas® HCV GT Control Kits

Dear Valued Customer,

## Executive Summary

Multiple complaints were received reporting positive control invalids while using select lots of the cobas® 4800 HCV GT test.

Previously, QN-RDS-Molecular Lab-2023-044 was released for this issue, instructing affiliates and customers to discontinue use of the cobas® 4800 System Sample Preparation Kit 2, lot J16283, which was noted to have been used by several customers reporting the invalid positive controls. Through the CAPA investigation, the root cause was ultimately determined to be related to the cobas® HCV GT Control Kits themselves, with the cobas® 4800 System Sample Preparation Kit 2, lot J16283 acting as a contributing factor.

Roche is requesting that customers discontinue use of and that customers and affiliates discard any remaining inventory of the cobas® HCV GT Control Kit lots J30965, K06929 and K09615, immediately.

## Subject

Multiple complaints were received reporting positive control invalids while using the cobas® 4800 HCV GT test. Review of available customer data showed an increase in invalid runs due to invalid positive controls associated with an R20 failure mode.

Previously, QN-RDS-MolecularLab-2023-044 was released for this issue, while investigating the cobas® 4800 System Sample Preparation Kit 2, lot J16283 as the suspected cause. Additional internal investigative testing was performed through CAPA 290009116 and the root cause was determined to be related to the cobas® HCV GT Control Kits, with the cobas® 4800 System Sample Preparation Kit 2 being a contributing factor.

Roche is requesting that customers discontinue use of any remaining inventory of the cobas® HCV GT Control Kits J30965, K06929 and K09615, and discard any remaining inventory immediately.

## Root Cause

The root cause was determined to be due to a drift in concentration of the Positive Control (PC) over time, caused by aging of the PC stock material and of the calibrators used in QC. The drift in the concentration of the PC stock material and calibrators, which are made from the same stock material, was slow and took several years to materialize into a performance issue in the field.

A contributing factor was determined to be the cobas® 4800 Sample Preparation 2 240T CE-IVD reagent kit lot J16283, which when used together with the cobas® HCV-GT test, caused the target Ct values to shift by approximately 1 Ct cycle (as previously described in QN-RDS-MolecularLab-2023-044). Although this effect is typical variability, for a PC with a low concentration, it increased the numbers of PC invalids as reported in the escalated cases.

# Discontinue use of select cobas® HCV GT Control Kits

## Risk Assessment

### Frequency of Occurrence

Positive control invalids while using the cobas® 4800 HCV GT test has been escalated through 53 global complaints to date.

### Detectability

The issue is highly detectable as the affected run will generate an R20 failure code for the cobas® 4800 HCV GT test positive control, which will invalidate the entire run.

### Severity

No patient or diagnostic test results are affected as the affected cobas® 4800 HCV GT test will be invalidated. As the HCV GT assay is not intended for diagnostic use, there is no risk in the delay of diagnosis. Patients being tested have already been diagnosed with HCV. Since HCV is a slow progressing disease, it would not have clinical implications and because there is no valid result generated, the test would be repeated. Therefore, medical risk to patients and users can be excluded.

As a result, an HHE is not required

## Actions

Discard any remaining cobas® HCV GT Control Kit lots J30965, K06929 and K09615.  
Provide the number of discarded kits and the lot number in the acknowledgment receipt.

## Contact

If you have any questions, please do not hesitate to contact your sales representative or our Customer Call Centre: **1800 88 8881**

Thank you.

Best regards,

**ROCHE DIAGNOSTICS (M) SDN. BHD.**



**Amal Safiyyah**  
MS Marketing Lead  
Email: [amal.safiyyah@roche.com](mailto:amal.safiyyah@roche.com)  
Tel. +603-7967 2388



**Ong Yean Ting**  
Head, Regulatory Affairs & Quality  
Email: [yeen\\_ting.ong@roche.com](mailto:yeen_ting.ong@roche.com)  
Tel. +603-7967 2390

# Discontinue use of select cobas® HCV GT Control Kits

## Customer Acknowledgement Receipt

Roche Diagnostics Malaysia  
Fax Back: +603 7967 2399  
Email: [malaysia.diagnostics@roche.com](mailto:malaysia.diagnostics@roche.com)

Attention: Customer Support Team

I acknowledge I have received notification on “**Discontinue use of select cobas® HCV GT Control Kits**” and will proceed as per recommended action.

Quantity of affected lot discarded.

| Lot Number | Number of kit discarded     |
|------------|-----------------------------|
| J30965     | Not distributed in Malaysia |
| K06929     |                             |
| K09615     |                             |

Thank you.

-----

Name:

Organization:

Stamp:

Date: